[Hereditary breast cancer: treatment and prevention].

In general, the treatment of early breast cancer is guided by the results from large randomised trials. The same does not apply to patients who carry BRCA1/2 mutations. The selection of loco-regional therapies might change according to BRCA1/2 mutation status. In order to reduce the risk of secondary breast and ovarian cancer, these patients may also be offered prophylactic oophorectomy. The possible impact of BRCA1/2 mutations on the efficacy of medical therapies has recently attained much interest, alongside the development of targeted therapies against BRCA1/2 associated cancers.